In fact this very same alert flew from our alert price of .275 to .50 in just 2 days for a 82% gain!
Sitting at just .319 this former winner could be a traders delight tomorrow morning!
AXXE a pharmaceutical company, engages in the marketing and distribution of various pharmaceutical products and diagnostic medical devices in Canada and internationally.
AXXE distributes dermatological, therapeutic nutritional, pain management, and diagnostic products.
AXXE’s principal product line includes Britical, Gravergol, Lactrase, Somnol, Triferexx, Urasal, Axspaz, Vivol, Hydraxx, Kemsol, Soropon, Amersol, Bactalase, Monurol, and Zynol, as well as skin care products.
AXXE distributes its products through physicians, hospitals, government and defense institutions, and pharmacies. The company was founded in 1997 and is headquartered in Markham, Canada.
Pain Management Now Worth BLN’S ($60 by 2015)
The highly fragmented pain-management market poses an opportunity for new classes of drugs targeting neuropathic pain as well as for generics as standard therapies come off patent. Because current therapies are often less than effective or have undesirable side effects, there also are emerging opportunities using genomics to match patients to pain medications.
Pain management today is dominated by Pfizer, Eli Lilly, Purdue Pharma, Endo Pharmaceuticals, Novartis, Johnson & Johnson, and Grünenthal. “Among these, Purdue Pharma, Endo, and Grünenthal specialize in pain,” points out Karen Holmes, senior market analyst and author of the recent Espicom Business Intelligence report, Evolution in the Pain Therapy Drugs Market: Nociceptive and Neuropathic Drug Development.
“Pfizer is by far the biggest player, consolidating its position with the acquisition of King Pharmaceuticals and Icagen. Including line extensions, Pfizer has at least 10 compounds in clinical development for pain indications.”
Whether those leaders will manage to maintain their positions depends upon how they manage their patent expirations as well as new drug development. “You have to be paranoid about the competition. The science isn’t stopping,” says John Steuart, managing partner, Claremont Creek Ventures. “Thousands of biotechs and tens of thousands of academic labs are working to develop new therapies all the time.” Pain management, he admits, is a mature market, so new therapies must be proven more efficacious or less toxic than existing medications.
Booming Market
Market projections vary, but Espicom estimated the global pain-management market at $46.4 BLN at the close of 2011. The U.S. market accounts for 48% of that. Another market analyst, Global Industry Analysts (GIA), one year ago predicted the global pain-management market would reach $60 BLN by 2015.
That predicted growth is based upon an aging global population, increasing number of surgeries, lifestyle changes, and a rising incidence of cancer. Some 1.5 BLN of the world’s 7 BLN people—21%—currently suffer from pain. That includes approximately 30% of all cancer patients and 60% of late-stage cancer patients.
The largest markets for pain-management medications currently are the U.S. and Europe. As with many pharmaceuticals, however, the fastest-growing markets are expected to be in Asia and Latin America, according to the GIA analysis, Pain Management: A Global Strategic Business Report. It anticipates a 9% compounded annual growth rate for pain-management therapies in Latin America between 2007 and 2015.
Recent AXXE News Developments
May 6th: TapouT Product Now Available in Select Vitamin World Stores
Begin your research on AXXE immediately and make sure you keep AXXE in full focus tomorrow morning!
="font-size:>
